Story thread · 3 reports / 3 sources
Encellin Partners with Breakthrough T1D to Advance Immune-Protected Cell Therapy for Type 1 Diabetes
financialpost.com · 4h
SAN FRANCISCO & NEW YORK & MONTREAL — Encellin, Inc., a clinical-stage biotechnology company developing Encapsulated Cell Replacement Therapy (ENCRT), today announced a partnership with Breakthrough T1D, the leading global Type 1 Diabetes (T1D) research and advocacy organization, and an award through its Industry Discovery and Development Partnership (IDDP) program to support the advancement of […]
First report: San Diego families rally for type 1 diabetes research ahead of Breakthrough T1D Walk — fox5sandiego.com, 2d
The coverage
The conversation · 0
Sign in to join the conversation.
No comments yet — start the thread.